92 related articles for article (PubMed ID: 3818495)
1. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.
Fernandes PB; Shipkowitz N; Bower RR; Jarvis KP; Weisz J; Chu DT
J Antimicrob Chemother; 1986 Dec; 18(6):693-701. PubMed ID: 3818495
[TBL] [Abstract][Full Text] [Related]
2. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
King A; Phillips I
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
[TBL] [Abstract][Full Text] [Related]
3. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.
Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of A-56619 (difloxacin) and A-56620, two aryl fluoroquinolones.
Digranes A; Dibb WL
Chemotherapy; 1988; 34(4):298-307. PubMed ID: 3208547
[TBL] [Abstract][Full Text] [Related]
5. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.
Hardy DJ; Swanson RN; Hensey DM; Ramer NR; Bower RR; Hanson CW; Chu DT; Fernandes PB
Antimicrob Agents Chemother; 1987 Nov; 31(11):1768-74. PubMed ID: 3435123
[TBL] [Abstract][Full Text] [Related]
6. Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro.
Bansal MB; Thadepalli H
Antimicrob Agents Chemother; 1987 Apr; 31(4):619-21. PubMed ID: 3606066
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
[TBL] [Abstract][Full Text] [Related]
8. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
Goldstein EJ
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
[TBL] [Abstract][Full Text] [Related]
9. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
[TBL] [Abstract][Full Text] [Related]
10. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
Dubreuil L; Devos J; Romond C; Bryskier A
Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
[TBL] [Abstract][Full Text] [Related]
11. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
Bassey CM; Baltch AL; Smith RP
J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
[TBL] [Abstract][Full Text] [Related]
12. The comparative in-vitro activity of ofloxacin.
Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
Seibert G; Limbert M; Klesel N
Eur J Clin Microbiol; 1983 Dec; 2(6):548-53. PubMed ID: 6230226
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
[TBL] [Abstract][Full Text] [Related]
17. In-vitro and in-vivo activities of T-3262, a new pyridone carboxylic acid.
Takahata M; Otsuki M; Nishino T
J Antimicrob Chemother; 1988 Aug; 22(2):143-54. PubMed ID: 3182417
[TBL] [Abstract][Full Text] [Related]
18. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
Soussy CJ; Deforges L; Le Van Thoi J; Duval J
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
[TBL] [Abstract][Full Text] [Related]
19. Is ciprofloxacin active against clinically important anaerobes?
Watt B; Brown FV
J Antimicrob Chemother; 1986 May; 17(5):605-13. PubMed ID: 2941400
[TBL] [Abstract][Full Text] [Related]
20. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
Fernandes PB; Swanson RN
Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
